For our first episode of season three, I sat down with Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech, where he leads the development of innovative therapies for cancer and inflammatory diseases. A physician-scientist and serial entrepreneur, Dr. Hanna previously founded the first academic drug development center at Duke University and has authored over 50 peer-reviewed publications. Under his leadership, Lamassu is advancing two novel therapeutics—RABI-767, now in Phase II trial, and SA53, a first-in-class oncology compound currently in Phase I/II trial. He also oversees Lamassu Pets, which is developing a canine therapy for pancreatitis. Dr. Hanna’s work is driven by a commitment to rapid, cost-effective drug development that addresses unmet clinical needs.

We discuss the mission of Lamassu Biotech, as well as the importance of academic accelerator programs, overcoming regulatory roadblocks, and the moral duty to accelerate drug development for patient care. Gabi emphasizes the need for efficient operations, strategic partnerships, and a patient-centric approach in biotech. We also explore the potential for policy changes to improve collaboration between universities and biotech companies, as well as the importance of ethical considerations in drug development. Dr. Hanna’s's insights provide valuable guidance for both entrepreneurs and those working in the biotech industry.

• Connect with Dr. Gabi Hanna on LinkedIn
• Follow Lamassu Biotech on LinkedIn
• Learn More about Lamassu Biotech

Connect with us!

Link In with Carina

Subscribe here:

• Apple
• Spotify
• Google Podcast
• RSS feed

Learn more about Recruitomics Consulting

Check out our reading list

Download our free startup resources guide to grow your biotech efficiently

If you're on the job market, visit the Collaboratory Career Hub

00:00 Introduction

00:13 Mission and Work at Lamassu Biotech

01:24 Previous Experience at Duke University

03:50 Challenges and Strategies in Biotech

06:48 Accelerating Drug Development

08:24 Navigating Regulatory Hurdles

14:19 The Role of the FDA and Knowledge Sharing

18:01 Maintaining US Biotech Leadership

27:15 Entrepreneurial Insights and Team Building

35:47 Final Thoughts and Contact Information

This week I had a great conversation with Russ Peloquin, Managing Partner of LifeSci Catalyst Partners. We dive into Russ's unique journey from aspiring exterminator (yes, you read that right!) to leading life science entrepreneur, discussing his extensive experience in commercialization, mergers, and acquisitions. Russ shares invaluable insights on the importance of marketing, fundraising strategies for biotech startups, the phases of taking a company from idea to commercialization, and the critical steps toward securing regulatory approvals. We also touch on the intersection of genome sequencing, blockchain, and AI, exploring how this convergence is set to democratize and capitalize on personal DNA. Whether you're new to biotech or an industry veteran, this episode offers a wealth of knowledge and practical advice on navigating the complex landscape of life sciences and startups.

• Get Russ's recommended book! Freakonomics: A Rogue Economist Explores the Hidden Side of Everything
• Learn more about LifeSci Catalyst Partners!
• Connect with Russ on LinkedIn!

Connect with us!

Link In with Carina

Subscribe here:

• Apple
• Spotify
• Google Podcast
• RSS feed

Learn more about Recruitomics Consulting

Check out our reading list

Download our free startup resources guide to grow your biotech efficiently

If you're on the job market, visit the Collaboratory Career Hub

00:00 Introduction and Early Aspirations

02:04 Journey into Medical Sales

03:37 Marketing and Commercialization Insights

05:31 Navigating Early-Stage Startups

08:39 Fundraising Strategies for Biotech Startups

15:00 Acquisitions and Exits

22:39 The Intersection of Genome Sequencing, Blockchain, and AI

29:49 Future Goals and Recommendations

31:47 Closing Remarks and Contact Information

This week I chatted with Renee Williams, Founder and Managing Partner at Williams Biotech Consulting. Renee is a seasoned fractional Chief Business Officer (CBO) for small and growing biotechnology companies. Renee shares her career path, insights into helping biotech startups secure funding and navigate partnerships, and the importance of adaptable strategies in a constantly evolving market. From term sheet negotiation to pitch deck reframes, Renee offers valuable advice and lessons for small companies. We also dissect her engagement tactics during major conferences like JP Morgan and the essential factors for biotech success.

• Get Renee's recommended book! The 3-Minute Rule: Say Less to Get More from Any Pitch or Presentation
• Link In with Renee!

Connect with us!

Link In with Carina

Subscribe here:

• Apple
• Spotify
• Google Podcast
• RSS feed

Learn more about Recruitomics Consulting

Check out our reading list

Download our free startup resources guide to grow your biotech efficiently

If you're on the job market, visit the Collaboratory Career Hub

00:00 Introduction and Childhood Dreams

01:19 The Power of Dressing the Part

01:49 Career Path and Consulting Firm

03:20 Role of a Fractional CBO

04:03 Navigating Startup Challenges

06:07 Crafting Effective Pitch Decks

08:32 Big Pharma vs. Biotech Mentality

16:01 The Importance of a Strong Team in Biotech

16:20 Approaching Pharma and Corporate Venture Capital

17:20 Strategies for Biotech Companies to Gain Traction

18:24 Types of Biotech CEOs and Their Approaches

21:02 Navigating Conferences and Networking

27:09 Future Goals and Aspirations

28:59 Book Recommendations and Closing Thoughts